Santini J.T.,Radiorx Inc.
Chemical Engineering Progress | Year: 2013
All drug delivery technologies aim to improve drug efficacy, minimize side effects, and reduce the burden of care for patients and physicians. For many drugs, the concentration in the body must be maintained nearly constant over long periods of time. In some cases, however, the best efficacy is achieved with repeated pulses of a drug at predetermined times or with an on-demand schedule based on symptoms or signals from chemical sensors. Pulsatile delivery is required for efficacy for the administration of parathyroid hormone. Frequent injections should be replaced with an alternative drug delivery approach that is less expensive, less invasive, and requires fewer office visits. A potential advantage of implantable devices for drug delivery is that the time between administrations can be greatly increased, which reduces the treatment burden on the patient and physician. Advances in novel device structures and materials, targeted nanoparticles, and gene therapy ensure that additional treatment options will be available in the future.
Radiorx Inc. | Date: 2012-10-05
The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
Radiorx Inc. | Date: 2012-05-18
The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an organonitro thioether compound described herein, such as a compound of Formula I or II. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of an organonitro thioether compound described herein, such as a compound of Formula I or II, to treat the cancer.
News Article | April 18, 2013
RadioRx’s focus is on the development of first-in-class compounds that affect capillary blood flow through the manipulation of cellular and blood levels of the free radical nitric oxide or NO and its downstream signaling pathways.
Oronsky B.,Radiorx Inc. |
Oronsky N.,CFLS LLC |
Scicinski J.,Radiorx Inc. |
Fanger G.,Radiorx Inc. |
And 2 more authors.
Translational Oncology | Year: 2014
In cancer chemotherapy, one axiom, which has practically solidified into dogma, is that acquired resistance to antitumor agents or regimens, nearly inevitable in all patients with metastatic disease, remains unalterable and irreversible, rendering therapeutic rechallenge futile. However, the introduction of epigenetic therapies, including histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTIs), provides oncologists, like computer programmers, with new techniques to “overwrite” the modifiable software pattern of gene expression in tumors and challenge the “one and done” treatment prescription. Taking the epigenetic code-as-software analogy a step further, if chemoresistance is the product of multiple nongenetic alterations, which develop and accumulate over time in response to treatment, then the possibility to hack or tweak the operating system and fall back on a “system restore” or “undo” feature, like the arrow icon in the Windows XP toolbar, reconfiguring the tumor to its baseline nonresistant state, holds tremendous promise for turning advanced, metastatic cancer from a fatal disease into a chronic, livable condition. This review aims 1) to explore the potential mechanisms by which a group of small molecule agents including HDACis (entinostat and vorinostat), DNMTIs (decitabine and 5-azacytidine), and redox modulators (RRx-001) may reprogram the tumor microenvironment from a refractory to a nonrefractory state, 2) highlight some recent findings, and 3) discuss whether the current “once burned forever spurned” paradigm in the treatment of metastatic disease should be revised to promote active resensitization attempts with formerly failed chemotherapies. © 2014 Neoplasia Press, Inc.